St. Louis, MO (PRWEB)
June 28, 2017
Supplies of the critical medical isotope molybdenum-99 (Mo-99) are secure and reliable according to a panel of leading experts gathered at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2017 annual meeting in Denver, Colorado in June. Mo-99 is the parent isotope of technetium-99m (Tc-99m), which is used in 30 to 40 million nuclear medicine procedures worldwide every year. (1)
Sally Schwarz, President of SNMMI, and Professor of Radiology at the Mallinckrodt Institute of Radiology at the Washington University School of Medicine in St. Louis, moderated the panel. The panel of top executives from Mo-99 producers addressed the specific steps that their companies are taking to ensure that the approximately 100,000 patients who rely on nuclear imaging testing worldwide each day will have access to the diagnostic care they need.
“It’s clear that the world’s Mo-99 producers have collaboratively used innovation, technology and careful planning to increase capacity and safeguard supplies of this critical medical isotope,” said Professor Schwarz.
Panelists included Jayne Senior, General Manager of ANSTO Nuclear Medicine; Frank de Lange, Vice President Manufacturing, Petten and Managing Director of Curium; Jean-Michel Vanderhofstadt, CEO of the Institute for Radio Elements (IRE); and Piet Louw, Executive Manager of NTP Radioisotopes.
Some of the strategies and investments being made to secure a stable and viable supply and market in the future included:
1. Increased Capacity. Current Mo-99 producers have made significant…